Conference Proceeding

The Role of Active Tetrapeptide of Pregnancy Specific Glycoprotein in Including Immunotolerance of Skin Allograft in Mice

Dr. Ruslan Alikhanov,
Head of Liver and pancreatic surgery department, MCSC, Moscow

Dr. Ruslan Alikhanov graduated Moscow Medical Stomatological Institute (now Moscow State University of Medicine and Dentistry) in 1998. He received General Surgery training and made his PhD at the Vishnevsky Surgery Institute. He made surgery observership in Department of General Surgery Johns Hopkins Hospital, Baltimore, USA in 2004. He completed a fellowship in liver surgery and transplantation (2010) at Chang Gung Memorial Hospital, Kaohsiung Medical Center, Taiwan and (2011) at University of Paris, Beaujon Hospital, France. In 2009, Dr. Alikhanov joined the Department of Surgery of M.V. Lomonosov Moscow Statement University as an Associated Professor. From 2013 until now Dr. Alikhanov is the head of liver and pancreatic surgery department in Moscow Clinical Scientific Center. Dr. Alikhanov clinical interests include liver transplantation, immunotolerance and oncology, laparoscopic hepatopancreatobiliry surgery. He has a strong commitment to teaching to medical students, residents and fellows.

Background: Pregnancy specific glycoproteins (PSGs) are synthesized by the placenta at the onset of pregnancy and are believed to play a role in maintaining a tolerogenic immune environment to prevent rejection of the fetus by the maternal immune system. Active part of PSG (tetrapeptidetyr-glu-cys-glu) was synthesized and investigated in terms of immunotolerogenic effect in mice.
Materials and Methods: The skin transplantation model was used to study the allograft rejection in female and male BALB\c mice. Gender-matched C57BL/ 6(H2b) mice were used as skin donors. The age of the animals was between eight and 12 weeks, weight over 20 g. The skin transplantation experiment conformed to local animal protection laws. Ten mice received in traperinoneal injection of PSG tetrapeptide during 14-20 days and 10 mice was rest in control group. The allograft rejection was evaluated macroscopically and by histological study.
Results: In control allogenic transplants, rejection times between 5 and 10 days were observed. In tetrapeptide allogenic transplants, rejection times between 14-21 days were observed and mice were stay tolerogenic until the injection of active tetrapeptide was stopped.
Conclusion: The active tetrapeptide of pregnancy specific glycoprotein may play role in inducing immunotolerance in transplantation. Further investigations planed to evaluate immunologic mechanisms of active tetrapeptide effects.

Published: 28 April 2017